Login
Companies $SER
$1.48 +$0.06 (4.23%) After hours
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc.

serinatx.com

What Do They Do?

Develops polymer-based drug candidates and delivery technology for neurological diseases, including Parkinson’s disease, and potential RNA-based and antibody-linked therapies.

How Do They Make Money?

Receives government grants that reimburse certain eligible project costs, with payments tied to research and development costs incurred for the funded projects.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $19.2M in FY2025.

Operating income, FY2025
−18478% of revenue
▼ −41% (Loss) vs FY2024 (−$17M, −30443%)
Net income, FY2025
−14755% of revenue
▼ −72% (Loss) vs FY2024 (−$11.1M, −19895%)
Free cash flow, FY2025
−13857% of revenue
▼ −5% (Loss) vs FY2024 (−$17.2M, −30641%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −72% (Loss)
vs −$4.6M in Q3 FY2025
  • Sep 9, 2026 Safety committee recommended advancing SER-252 to the next study cohort The committee reviewed Cohort 1 of the Parkinson’s disease study; topline data from the single-ascending-dose portion are expected in the first half of 2027.

Shrinking. Revenue fell 10% in 4 years, from $144K in FY2021 to $130K in FY2025, about 3% a year.

From regenerative medicine to drug delivery The older report described cell therapies and regenerative technologies for aging-related diseases. The newer report centers on POZ-enabled drug candidates for neurological diseases and other indications.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support